Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases.

Huiart L, Ferdynus C, Renoux C, Beaugrand A, Lafarge S, Bruneau L, Suissa S, Maillard O, Ranouil X.

BMJ Open. 2018 Mar 30;8(3):e018180. doi: 10.1136/bmjopen-2017-018180.

2.

Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department.

Vinson DR, Warton EM, Mark DG, Ballard DW, Reed ME, Chettipally UK, Singh N, Bouvet SZ, Kea B, Ramos PC, Glaser DS, Go AS.

West J Emerg Med. 2018 Mar;19(2):346-360. doi: 10.5811/westjem.2017.9.35671. Epub 2018 Feb 12.

3.

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG, Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

BMJ Open. 2017 Dec 21;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.

4.

Atrial fibrillation decision support tool: Population perspective.

Eckman MH, Costea A, Attari M, Munjal J, Wise RE, Knochelmann C, Flaherty ML, Baker P, Ireton R, Harnett BM, Leonard AC, Steen D, Rose A, Kues J.

Am Heart J. 2017 Dec;194:49-60. doi: 10.1016/j.ahj.2017.08.016. Epub 2017 Aug 23.

PMID:
29223435
5.

Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective.

CantĂș-Brito C, Silva GS, Ameriso SF.

Clin Appl Thromb Hemost. 2018 Jan;24(1):22-32. doi: 10.1177/1076029617734309. Epub 2017 Oct 9.

6.

Effect of a combined education and eHealth programme on the control of oral anticoagulation patients (PORTALS study): a parallel cohort design in Dutch primary care.

Talboom-Kamp EPWA, Verdijk NA, Kasteleyn MJ, Harmans LM, Talboom IJSH, Numans ME, Chavannes NH.

BMJ Open. 2017 Sep 27;7(9):e017909. doi: 10.1136/bmjopen-2017-017909.

7.

Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.

Ueberham L, Dagres N, Potpara TS, Bollmann A, Hindricks G.

Adv Ther. 2017 Oct;34(10):2274-2294. doi: 10.1007/s12325-017-0616-6. Epub 2017 Sep 27. Review.

8.

Association between subjective risk perception and objective risk estimation in patients with atrial fibrillation: a cross-sectional study.

Zweiker D, Zweiker R, Winkler E, Roesch K, Schumacher M, Stepan V, Krippl P, Bauer N, Heine M, Reicht G, Zweiker G, Sprenger M, Watzinger N.

BMJ Open. 2017 Sep 25;7(9):e018242. doi: 10.1136/bmjopen-2017-018242.

9.
10.

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.

Gilligan AM, Gandhi P, Song X, Wang C, Henriques C, Sander S, Smith DM.

Am J Cardiovasc Drugs. 2017 Dec;17(6):481-492. doi: 10.1007/s40256-017-0244-1.

11.

PURLs: Direct oral anticoagulants or warfarin for A fib?

Lyon C, Reed A, Prasad S.

J Fam Pract. 2017 Aug;66(8):518-519.

12.
13.

Balancing Anticoagulation Decisions in Patients on Dialysis with Atrial Fibrillation.

Deal EN, Shuster JE.

J Am Soc Nephrol. 2017 Jul;28(7):1957-1959. doi: 10.1681/ASN.2017040451. Epub 2017 Jun 5. No abstract available.

PMID:
28583916
14.

Prevalence and Clinical Intentions of Antithrombotic Therapy on Discharge to Hospice Care.

Kowalewska CA, Noble BN, Fromme EK, McPherson ML, Grace KN, Furuno JP.

J Palliat Med. 2017 Nov;20(11):1225-1230. doi: 10.1089/jpm.2016.0487. Epub 2017 Jun 5.

PMID:
28581881
15.
16.

Stroke Prevention in Atrial Fibrillation: Focus on Latin America.

Massaro AR, Lip GYH.

Arq Bras Cardiol. 2016 Dec;107(6):576-589. doi: 10.5935/abc.20160116. Epub 2016 Aug 11. Review. Portuguese, English.

17.

Use of dabigatran vs. warfarin with low-molecular-weight heparin bridging in catheter ablation for atrial fibrillation patients with a low CHADS2 score.

Hao L, Rong B, Xie F, Lin MJ, Zhong JQ.

Biomed Rep. 2017 May;6(5):549-554. doi: 10.3892/br.2017.880. Epub 2017 Mar 28.

18.

Sex differences in management and outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events (Gulf SAFE).

Shehab A, Zubaid M, Bhagavathula AS, Rashed WA, Alsheikh-Ali AA, AlMahmeed W, Sulaiman K, Al-Zakwani I, AlQudaimi A, Asaad N, Amin H; Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) investigators.

PLoS One. 2017 May 17;12(5):e0175405. doi: 10.1371/journal.pone.0175405. eCollection 2017.

19.

Cardioversion in Acute Atrial Fibrillation Without Anticoagulation.

Airaksinen KJ, Nammas W, Nuotio I.

J Atr Fibrillation. 2013 Dec 31;6(4):970. doi: 10.4022/jafib.970. eCollection 2013 Dec. Review.

20.

Anticoagulation and Clinical Outcomes in Heart Failure Patients With Atrial Fibrillation: Findings From the ADHERE Registry.

Eapen ZJ, Mi X, Fonarow GC, Setoguchi S, Piccini JP, Mills RM, Klaskala W, Curtis LH, Hernandez AF.

J Atr Fibrillation. 2013 Dec 31;6(4):953. doi: 10.4022/jafib.953. eCollection 2013 Dec.

Supplemental Content

Support Center